Specialist healthcare investor Gilde Healthcare has agreed to carve out blood group and immune reagents business Sanquin Reagents from Sanquin Health Solutions.
The Dutch company provides materials for diagnostic research and drug development in the fields of hematology and immunology.
Sanquin is Gilde Healthcare’s debut deal from its €517m Fund IV, which it closed in March this year.
Firm partner Hugo de Bruin said, “We invest in companies that enable better healthcare at lower cost.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
“Sanquin Reagents’ strong R&D focus on developing new reagents fits with this investment philosophy.
“We see ample opportunity to expand the unique research and production capabilities and develop new reagents.”
GHPE IV was more than double the size of its predecessor Fund III, which Gilde Healthcare closed on €200m in 2019.
The vehicle is focuses on investments in profitable lower mid-market healthcare companies in North-west Europe with an EBITDA of €2m to €15m.
It is targeting healthcare subsectors including healthcare provision, service providers, and manufacturers of medical supplies and pharmaceutical companies.
Source: AltAssets
Can’t stop reading? Read more
Carlyle and Goldman Sachs open private credit funds to Willow users with $10,000 minimum
Carlyle and Goldman Sachs open private credit funds to Willow users with $10,000 minimum Carlyle,...
EQT, PAI, and Stone Point shortlisted for €2bn takeover of Castik-backed Global Group
EQT, PAI, and Stone Point shortlisted for €2bn takeover of Castik-backed Global Group EQT, PAI...
CAIS Advisors unveils retail vehicle giving investors a stake in elite sports and media
CAIS Advisors unveils retail vehicle giving investors a stake in elite sports and media Eldridge...